Related Experiment Videos
Buspirone in the management of major depression: a placebo-controlled comparison
1Fabre Clinic, Houston, TX 77004.
Insights
Buspirone significantly reduced depression symptoms in outpatients compared to placebo, particularly in melancholic patients. Common side effects included CNS and gastrointestinal issues, but no serious adverse events were reported.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Major depressive disorder (MDD) is a prevalent mental health condition.
- Anxiety symptoms frequently co-occur with depression, complicating treatment.
- Buspirone, an anxiolytic, has been investigated for its efficacy in depression.
Purpose of the Study:
- To evaluate the efficacy and safety of buspirone in treating major depression.
- To assess buspirone's effectiveness in patients with comorbid anxiety symptoms.
- To compare buspirone's effects against a placebo in a double-blind study.
Main Methods:
- A randomized, double-blind, placebo-controlled trial was conducted over 8 weeks.
- 140 outpatients with major depression (HAM-D ≥ 18, HAM-A ≥ 18) were enrolled.
- Flexible dosing of buspirone (5-90 mg/day) was administered, with a mean dose of 41-54 mg/day.
Main Results:
- Buspirone showed significant reductions in Hamilton Rating Scale for Depression (HAM-D) scores at Weeks 2, 3, 4, and 6 compared to placebo.
- Melancholic patients treated with buspirone demonstrated significantly greater HAM-D score improvements.
- Central nervous system (CNS) and gastrointestinal effects were the most common adverse experiences.
Conclusions:
- Buspirone is an effective treatment for major depression, especially in patients with melancholic features and comorbid anxiety.
- The drug is generally well-tolerated, with manageable side effects such as dizziness and nausea.
- Further research may explore buspirone's role in specific depressive subtypes.
Abstract:
One hundred forty outpatients with major depression were admitted to an 8-week, placebo-controlled, double-blind study of buspirone. Entry criteria included a Hamilton Rating Scale for Depression (25-item [HAM-D]) score of greater than or equal to 18 and a Hamilton Rating Scale for Anxiety (HAM-A), score of greater than or equal to 18. A flexible dose schedule ranging from 5-90 mg/day was employed. The mean dose of buspirone was 41-54 mg/day from Week 2 to the end of the study. Sixty-four percent of buspirone patients and 50% of placebo patients were melancholic; 64% of buspirone patients and 74% of placebo patients discontinued treatment before the end of the study. Extender data analysis showed that buspirone patients had significant (p less than .05) HAM-D score reductions compared with the placebo group at Weeks 2, 3, 4, and 6. The HAM-D retardation factor trended toward significance over placebo at Weeks 3, 4, and 6. HAM-D change scores for the subgroup of melancholic patients taking buspirone were significantly (p less than .02) better than those of the placebo-treated melancholic subjects at Weeks 2, 3, 4, and 6. Most other efficacy parameters also favored the buspirone-treated group over the placebo-treated group. The most common adverse experiences for the buspirone group were CNS effects (74% in the buspirone group vs. 21% in the placebo group) and gastrointestinal effects (55% in the buspirone group vs. 37% in the placebo group). Side effects consisted of dizziness, light-headedness, nausea, and headache. No serious or unexpected adverse effects occurred.(ABSTRACT TRUNCATED AT 250 WORDS)